12 completed, 5 terminated, 2 active not recruiting. 19 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 12, Terminated 5, Active not recruiting 2 |
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Terminated 1 |
Follow T-Cell Large Granular Lymphocyte Leukemia: new trials by email Literature Review of T-Cell Large Granular Lymphocyte Leukemia trials Research Report on T-Cell Large Granular Lymphocyte Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia Oral Azacitidine - T-Cell Large Granular Lymphocyte Leukemia | Phase 1 / Phase 2 | Active not recruiting | Jonathan Brammer | 11 | 2022-06-29 | 2026-10-21 |
| A Study of Ruxolitinib and Duvelisib in People With Lymphoma Ruxolitinib, Duvelisib - T-cell Lymphomas, NK-Cell Lymphomas | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 80 | 2021-08-12 | 2026-11-05 |
| CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 1 | Completed | Wake Forest University Health Sciences | 16 | 2014-09-01 | 2024-02-13 |
| MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Morphotek | 27 | 2013-11-01 | 2016-01-08 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Ipilimumab and Local Radiation for Selected Solid Tumors Ipilimumab, Radiation therapy - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Terminated | Stanford University | 3 | 2013-02-01 | 2024-01-24 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma Alisertib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 34 | 2012-04-16 | 2018-04-11 |
| Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study - Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Phase 1 | Completed | National Cancer Institute (NCI) | 17 | 2010-11-24 | 2017-09-25 |
| Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma azacitidine, bortezomib, Correlative studies - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Pierluigi Porcu | 8 | 2010-05-01 | 2013-12-03 |
| Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 129 | 2010-03-01 | 2014-11-05 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy sunitinib malate, pharmacological study, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2009-08-01 | 2014-03-17 |
| Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Dasatinib, Pharmacological Study - Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 80 | 2008-10-01 | 2015-07-02 |
| Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma bevacizumab, cediranib maleate - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 57 | 2007-05-01 | 2014-02-19 |
| Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma oxaliplatin, etoposide - Angioimmunoblastic T-cell Lymphoma, B-cell Childhood Acute Lymphoblastic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 40 | 2004-11-01 | 2014-02-24 |
| Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 37 | 2003-09-01 | 2020-01-18 |
| Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction imatinib mesylate, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 60 | 2001-08-01 | 2013-02-07 |
| Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer total-body irradiation, fludarabine phosphate, cyclosporine - Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 21 | 2000-05-01 | 2020-01-21 |
| Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies indium In 111 anti-CD45 monoclonal antibody BC8, yttrium Y 90 anti-CD45 monoclonal antibody BC8, peripheral blood stem cell transplantation - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 2 | 1999-09-01 | 2021-04-02 |
Leukemia, Large Granular Lymphocytic (19) · Lymphoma, Large-Cell, Anaplastic (17) · Mycosis Fungoides (16) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (16) · Sezary Syndrome (16) · Burkitt Lymphoma (15) · Immunoblastic Lymphadenopathy (15) · Lymphoma, T-Cell, Cutaneous (15) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (15) · Leukemia, Hairy Cell (14) · Lymphoma, Extranodal NK-T-Cell (14) · Leukemia, Lymphocytic, Chronic, B-Cell (13) · Lymphoma, B-Cell, Marginal Zone (13) · Lymphoma, Follicular (13) · Lymphoma, Mantle-Cell (13)
Hematologic Diseases (19) · Hemic and Lymphatic Diseases (19) · Immune System Diseases (19) · Immunoproliferative Disorders (19) · Leukemia (19) · Leukemia, Lymphoid (19) · Leukemia, T-Cell (19) · Lymphatic Diseases (19) · Lymphoproliferative Disorders (19) · Neoplasms (19) · Neoplasms by Histologic Type (19) · Lymphoma (18) · Disease Attributes (16) · Pathologic Processes (16) · Pathological Conditions, Signs and Symptoms (16)
Peripheral Blood Stem Cell Transplantation (3) · Azacitidine (2) · Cyclosporine (2) · Mycophenolic Acid (2) · Whole-Body Irradiation (2) · fludarabine phosphate (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · Bendamustine Hydrochloride (1) · Bevacizumab (1) · Bortezomib (1) · Brentuximab Vedotin (1) · CTLA-4 Antigen (1) · Calcium Dobesilate (1) · Dasatinib (1) · Dexamethasone (1)
National Cancer Institute (NCI) (8) · Fred Hutchinson Cancer Center (3) · City of Hope Medical Center (1) · Jonathan Brammer (1) · Memorial Sloan Kettering Cancer Center (1) · Morphotek (1) · Northwestern University (1) · Pierluigi Porcu (1) · Stanford University (1) · Wake Forest University Health Sciences (1)
United States (19) · Italy (2) · Canada (1) · Germany (1)
Adam Petrich, MD (1) · Ajay Gopal (1) · Alison Moskowitz, MD (1) · Brenda Sandmaier (1) · David Hong (1) · David Maloney (1) · George A. Fisher, MD, PhD (1) · John Deeken (1) · John Sarantopoulos (1) · Jonathan Brammer, MD (1) · Leslie Andritsos (1) · Lisa McGregor (1) · Najat Daw (1) · Pierluigi Porcu (1) · Rakhee Vaidya (1)
PMID 32499241, PMID 22259028, PMID 24474568, PMID 26853648, PMID 29292843, PMID 30562587, PMID 31617432
P30CA015704 (3), U01CA062505 (2), U01CA097452 (2), P01CA018029 (1), P01CA044991 (1), P01CA078902 (1), P30CA012197 (1), P30CA016058 (1), P30CA016672 (1), P30CA021765 (1), P30CA033572 (1), U01CA062461 (1), U01CA062487 (1), U01CA062491 (1), U01CA062502 (1)